Immunotherapy for Cancer: CAR-T, Checkpoint Inhibitors, a...

Cancer Treatment · 3 · August 10, 2025

Checkpoint inhibitors — drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) — have transformed survival for melanoma, lung cancer, and kidney cancer. Five-year survival for metastatic melanoma jumped from 5% to 40% in a decade. But access and affordability vary enormously worldwide.

Checkpoint Inhibitors: The Broad-Spectrum Revolution

Pembrolizumab (Keytruda) is now approved for 16 cancer types — the broadest indication of any cancer drug. It works by blocking PD-1, a protein that cancer cells use to hide from the immune system. Annual cost in the US: $150,000-$190,000. In India, biosimilar pembrolizumab (Synthon) costs approximately $1,200-$2,000 per cycle vs $10,000-$13,000 in the US for brand Keytruda.

Not all cancers respond. Biomarkers matter: PD-L1 expression above 50% predicts 45% response rate. Microsatellite instability-high (MSI-H) tumors respond regardless of cancer type — this is why Keytruda received the first tissue-agnostic FDA approval. Without biomarker testing, you're guessing.

CAR-T Cell Therapy: The Living Drug

CAR-T therapy engineers a patient's own T-cells to recognize and attack cancer. It achieves complete remission in 40-54% of patients with relapsed/refractory B-cell lymphoma or leukemia — patients who've failed all other treatments. Cost in the US: $475,000-$530,000 for the therapy alone. In India, the recently launched NexCAR19 (developed by ImmunoACT/IIT Bombay) costs approximately $30,000-$40,000. China offers CAR-T at $60,000-$100,000.

Accessing Immunotherapy Abroad

Two scenarios drive immunotherapy tourism: (1) cost — US patients seeking biosimilar checkpoint inhibitors at 80-90% savings, and (2) access — patients in countries where specific immunotherapies aren't yet approved seeking treatment elsewhere. India's Tata Memorial Hospital and HCG Cancer Centre are the leading immunotherapy destinations for international patients, offering both checkpoint inhibitors and clinical trials for novel combinations at a fraction of Western pricing.

Cost Comparison

| Country | Cost Range (Pembrolizumab (annual))

| United States | $150,000–$190,000

| India | $15,000–$25,000

| Turkey | $30,000–$50,000

| Mexico | $40,000–$60,000

Key Takeaways

- Checkpoint inhibitors transformed metastatic melanoma survival from 5% to 40% at 5 years

- Biosimilar pembrolizumab in India costs $1,200-$2,000 per cycle vs $10,000-$13,000 in the US

- CAR-T therapy achieves 40-54% complete remission — now available in India at $30,000-$40,000

- Biomarker testing (PD-L1, MSI-H) is essential to predict immunotherapy response

Compare real-time pricing using our global cost calculator.